As previously announced, low dose D-cycloserine has been associated with augmentation of the antidepressant and antisuicidal ...

TORONTO, April 3, 2023 /PRNewswire/ - Greenbrook TMS Inc. (NASDAQ: GBNH) ("Greenbrook" or the "Company") today announced that the Company has amended its amended and restated master sales agreement ...

NRx Pharmaceuticals (NRXP) amended its Investigational New Drug filing for NRX-101 to include the use of NRX-101 in association with Transcranial Magnetic Stimulation for the treatment of depression, ...

With its policy change, Cigna now joins several other major insurers that cover the device, including Centene, Highmark, Blue Cross Blue Shield, Tricare and Palmetto GBA. More than 86 million adults ...

While devices that stimulate the brain invasively have generally been available since 2002, and devices that do so non-invasively have been available since 2013, in recent years, the U.S. Food and ...

Munich, Germany; Atlanta, Georgia - September 10, 2025 – neurocare group AG (“neurocare” or the “Company”), a leading innovator in personalized mental health and performance, today announced it has ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted clearance to a transcranial magnetic stimulation device as an adjunctive treatment for major ...

NeuroStar Advanced Therapy is a transcranial magnetic stimulation system that uses magnetic fields to induce neural activity in the cerebral cortex. The Food and Drug Administration (FDA) has cleared ...

Researchers from Aalto University and the University of Wisconsin utilised a TMS-EEG device, which combines transcranial magnetic stimulation and EEG, to examine how the brain activity of people in ...

TMS offers a safe, non-invasive, and drug-free alternative, with no black box warning and no medication-related side effects. Clinical studies show that approximately 60% of patients achieve remission ...